Brazil allows sale of cannabis-based MS drug

Brazil’s health care regulator, Anvisa, handed out the nation’s first license for the sale of a cannabis-based drug – one designed for the treatment of multiple sclerosis.

According to Reuters, U.K.-based GW Pharmaceuticals PLC developed the marijuana-based oral spray, which is known internationally as Sativex. It will be marketed in Brazil as Mevatyl.

Anvisa announced Monday it had issued a license to São Paulo-based Beaufour Ipsen Farmacêutica to sell and distribute the drug.

Sativex is already sold in 28 other countries, according to Anvisa.

For several years, Brazilian patients have waged a legal battle to get around prohibitions targeting cannabis-based medicines. But in the past couple of years, according to Reuters, Anvisa has loosened some restrictions and allowed patients with medical recommendations to import marijuana-based medicines.

Brazil decriminalized growing and possessing small amounts of cannabis and other drugs more than a decade ago, Reuters reported. But buying and selling cannabis is still not allowed.

Daily News | Briefs | Medical Cannabis Business & Marijuana Legal News in Other Regions

 1 Comment

  1. Angelo January 19, 2017

Leave a Reply

Your email address will not be published. Required fields are marked *

Please note: Comments are moderated by our editors who do their best to approve comments ASAP. As Marijuana Business Daily is focused on business, we approve comments that are specifically relevant to industry professionals. General opinions and questions about cannabis may not be posted.